Sera Prognostics Inc. (SERA)
undefined
undefined%
At close: undefined
8.62
0.35%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes.

The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.

It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.

The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc.
Sera Prognostics Inc. logo
Country United States
IPO Date Jul 15, 2021
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 55
CEO Evguenia Lindgardt M.B.A.

Contact Details

Address:
2749 East Parleys Way
Salt Lake City, Utah
United States
Website https://seraprognostics.com

Stock Details

Ticker Symbol SERA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534969
CUSIP Number 81749D107
ISIN Number US81749D1072
Employer ID 26-1911522
SIC Code 8071

Key Executives

Name Position
Evguenia Lindgardt M.B.A. President, Chief Executive Officer & Director
Austin Aerts Chief Financial Officer
Robert G. Harrison Chief Information Officer
Benjamin G. Jackson J.D. General Counsel
Dr. Gregory C. Critchfield M.D., M.S. Executive Director
Dr. John J. Boniface Ph.D. Chief Scientific Officer
Dr. Paul Kearney Ph.D. Chief Data Officer

Latest SEC Filings

Date Type Title
Dec 12, 2024 4 Filing
Dec 12, 2024 4 Filing
Dec 09, 2024 4 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing